Levofolinato De Cálcio Farmoz (Calcium Levofolinate)

Calcium levofolinate is converted inside cells to a reduced folate form that bypasses dihydrofolate reductase inhibition. This restores normal DNA synthesis in healthy tissues during methotrexate therapy and stabilises the binding of 5‑fluorouracil metabolites to thymidylate synthase, increasing chemotherapy effectiveness.

The dose of calcium levofolinate is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and the concurrent chemotherapy regimen. Only a qualified health‑care professional should determine the appropriate dosing schedule.

Safety data for calcium levofolinate in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Calcium levofolinate is the most widely used folate rescue agent because it provides a stable, reduced folate cofactor that directly bypasses methotrexate inhibition. Compared with oral folic acid, it offers faster intracellular availability and is preferred for high‑dose methotrexate protocols and for synergising with 5‑fluorouracil.

Levofolinato De Cálcio Farmoz must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. If the product reaches room temperature for a short period, it may be used, but it should be returned to refrigeration promptly.

The injectable solution is given either intravenously or intramuscularly by a qualified health‑care professional. The route, infusion rate and dilution are determined by the prescribing protocol and the patient’s clinical status.

Serious adverse events include anaphylactic reactions, acute renal toxicity, severe hepatic dysfunction, marked hypotension, pulmonary edema and significant electrolyte disturbances. Prompt recognition and medical intervention are essential if any of these occur.

Patients with known hypersensitivity to calcium levofolinate or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal or hepatic impairment, and it should not be administered concurrently with high‑dose methotrexate without appropriate rescue planning.